Clinical trial NCT05317559: Cardiometabolic Outcomes With Light Exposure During Sleep
Official title: Cardiometabolic Outcomes With Light Exposure During Sleep
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Light
Keywords: light
sleep
metabolism
sympathetic nervous system
insulin resistance
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2022-04-08
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study tested the hypothesis that acute exposure to light during nighttime sleep adversely affects cardiometabolic function.

Detailed description: This study tested the hypothesis that acute exposure to light during sleep adversely affects next morning glucose homeostasis and whether this effect occurs via reduced sleep quality, melatonin suppression, or sympathetic nervous system (SNS) activation during sleep. Twenty young adults participated in this parallel-group study design. The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.

Eligibility criteria: Inclusion Criteria:

* healthy adults
* ages 18-40 years
* habitual sleep duration of 6.5-8.5 hours
* habitual sleep onset of 9:00 pm-1:00 am

Exclusion Criteria:

* any sleep disorder as assessed by history and screening questionnaires for obstructive sleep apnea (Berlin) and excessive daytime sleepiness (ESS \>12), and by PSG to exclude sleep apnea (apnea hypopnea index ≥ 15), periodic leg movements (movement arousal index ≥ 15), or REM sleep behavior disorder;
* history of a cognitive or neurological disorder;
* history of a major psychiatric disorder, including but not limited to mood/anxiety, eating, and alcohol/substance abuse disorders;
* depressed mood (Beck Depression Inventory II score ≥ 20);
* diabetes or other endocrine disorders;
* any gastrointestinal disease requiring dietary adjustment;
* blindness or significant vision loss;
* any unstable or serious medical conditions;
* current or recent (within the past month) of psychoactive, hypnotic, stimulant or analgesic medications;
* shift work or other types of self-imposed irregular sleep schedules;
* obesity (body mass index \> 30 kg/m2);
* history of habitual smoking (6 or more cigarettes per week) or drinking (7 or more alcoholic beverages per week) or caffeine consumption greater than 300 mg per day;
* current use of light therapy;
* use of any other legal or illicit substance that may affect sleep and/or appetite;
* allergy to heparin.
* Due to the metabolic stress associated with pregnancy and breastfeeding, patients who were pregnant or breastfeeding were also excluded.

Primary outcomes:
measure: Matsuda Index
timeFrame: Day 2
measure: Matsuda Index
timeFrame: Day 3
measure: HOMA-IR
timeFrame: Day 2
measure: HOMA-IR
timeFrame: Day 3
Secondary outcomes:
measure: Sleep Stages
timeFrame: Night 1
measure: Sleep Stages
timeFrame: Night 2
measure: Sleep Stages
timeFrame: Night 3
measure: Heart Rate
timeFrame: Night 2
measure: Heart Rate
timeFrame: Night 3
measure: Blood pressure
timeFrame: Day 2
measure: Blood pressure
timeFrame: Day 3
measure: Slow Wave Activity
timeFrame: Night 1
measure: Slow Wave Activity
timeFrame: Night 2
measure: Slow Wave Activity
timeFrame: Night 3
Other outcomes:
measure: Melatonin
timeFrame: Day 2
measure: Melatonin
timeFrame: Day 3
measure: subjective sleepiness
timeFrame: Day 2
measure: subjective sleepiness
timeFrame: Day 3
measure: hunger
timeFrame: Day 2
measure: hunger
timeFrame: Day 3
Locations:
Study officials:
References: